clinical benefit of teclistamab vs real-world physician’s choice for r/r multiple myeloma
Published 1 year ago • 297 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
4:13
real-world study determining the safety and efficacy of teclistamab in r/r multiple myeloma
-
1:00
the recent fda approval of teclistamab for r/r multiple myeloma
-
0:46
2-year follow-up of majestec-1: teclistamab in r/r multiple myeloma
-
0:45
fda approval of teclistamab for r/r multiple myeloma and the value of immunotherapies
-
6:38
real-world efficacy & safety of teclistamab in patients with heavily pretreated r/r multiple myeloma
-
1:43
safety and efficacy of teclistamab in patients with triple-class exposed r/r myeloma
-
4:16
what is the monoclonal antibody talvey™ (talquetamab)?
-
23:13
bispecific antibodies in multiple myeloma | dana-farber cancer institute
-
4:33
brawm: bendamustine, rituximab and acalabrutinib for waldenström’s macroglobulinemia
-
1:45
the value of teclistamab in r/r myeloma & strategies to mitigate toxicities
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:52
first-in-human results of the anti-bcma antibody-drug conjugate hdp-101 in r/r myeloma
-
5:54
redirectt-1 results: teclistamab talquetamab in r/r multiple myeloma
-
5:38
teclistamab for r/r myeloma
-
2:04
approval of teclistamab in triple-class refractory multiple myeloma
-
3:17
teclistamab in relapsed/refractory multiple myeloma
-
0:41
fcrh5 & gprc5d bispecific antibodies: antigen targets beyond bcma for multiple myeloma
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
3:45
update on phase i trial of teclistamab in r/r myeloma
-
1:04
majestec-1: teclistamab for myeloma